oncology

Immuno-oncology harnesses immunity to fight cancer. Biointron explores how antibodies reshape oncology through immune system activation.

The 12th Immuno-Oncology Summit in Philadelphia spotlighted antibody therapeutics. Biointron shares event highlights driving progress in cancer immunotherapy.

Antibody-drug conjugates (ADCs) have revolutionized the landscape of oncology by delivering targeted therapies that minimize damage to healthy cells while maximizing the impact on cancerous tissues. However, researchers and clinicians are now exploring the many therapeutic possibilities of ADCs in treating a variety of non-cancerous conditions such as autoimmune, infectious, neurological, cardiovascular, and metabolic diseases.

The Next-Gen Immuno-Oncology Conference 2024 in Boston featured advances in immunotherapy. Biointron shares insights driving future antibody-based treatments.

BIO 2024 in San Diego showcased biotech innovation. Biointron reports highlights on antibody discovery, engineering, and collaborations shaping the future of biologics.

Agonist antibodies activate receptors to modulate biology. Biointron explores their mechanisms, therapeutic promise, and applications in immune regulation and oncology.